French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients

Active, not recruitingOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2024

Conditions
GISTGIST, MalignantPDGFR-Alpha D842V
Interventions
DRUG

Patient treated by Avapritinib in real life

"The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.~Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA."

Trial Locations (7)

69008

Centre Léon Bérard, Lyon

Unknown

CHRU Besançon, Besançon

Insitut Bergonié, Bordeaux

CHU Clermont Ferrand, Clermont-Ferrand

Institut de Cancérologie de l'Ouest (ICO), Nantes

CHU Robert Debré, Reims

Institut Gustave Roussy, Villejuif

Sponsors
All Listed Sponsors
collaborator

Blueprint Medicines Corporation

INDUSTRY

lead

Centre Leon Berard

OTHER